Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 2 | Cell & Bioscience

Fig. 2

From: Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

Fig. 2

New concept: selective depletion of Tregs in the tumor microenvironment results in tumor immunity. Higher levels of CTLA-4 on intratumoral Tregs allow their selective depletion by anti-CTLA-4 antibodies, perhaps through antibody-dependent cellular phagocytosis (ADCP) by macrophages and/or antibody-dependent cellular cytotoxicity (ADCC) by NK cells. Blocking of B7-CTLA-4 interaction is not required for effective depletion of intratumoral Treg cells

Back to article page